A microdose is gone from the body within hours, so any lasting benefit cannot come from the drug being continuously present — it would have to come from a durable change the drug leaves behind. Two candidate changes dominate the discussion: an alteration of activity and connectivity within the default mode network, the brain system tied to rumination, and an increase in neural plasticity — the growth of new connections between neurons, associated with the growth factor BDNF. The preclinical evidence for psychedelic-induced plasticity is genuinely strong, and the full-dose human imaging of network effects is solid. What is thin is the human, sub-perceptual evidence: the structural findings come from cells and animals, the network findings from perceptual doses, and the one human low-dose BDNF result is preliminary and has not consistently replicated. This article lays out the mechanism that could explain a lasting effect — and is careful about how far it has actually been shown.
The puzzle a plasticity mechanism is meant to solve
There is a specific problem any explanation of microdosing has to solve. The drug clears quickly — psilocin’s pharmacokinetics give it a presence of only a few hours, as set out in the pharmacokinetics article. Yet the benefits people report are described as cumulative, building over weeks. A substance that is absent most of the time cannot produce an ongoing effect through its mere presence. So the effect, if real, must be carried by something the drug changes and then leaves behind. Neuroplasticity is the leading candidate for that “something,” because it is, by definition, a durable change in the brain’s wiring that can outlast the trigger that caused it.
This is what makes the plasticity hypothesis attractive: it is the right shape of mechanism for the claim. The question is whether the evidence shows it actually operates at sub-perceptual doses in humans, and there the picture is uneven.
Neuroplasticity means change, not automatically improvement
One clarification has to come first, because it is the most common misreading of this entire area. Neuroplasticity refers to the brain’s capacity to reorganize its connections. That capacity is essential for learning and adaptation, but it is direction-neutral: plasticity is the ability to change, not a guarantee that the change is good. Whether a given change is beneficial depends on which circuits change, under what conditions, and how those changes feed into behaviour. “More plasticity” is therefore not synonymous with “a healthier brain,” and a finding that a compound increases plasticity is not, by itself, a finding that it helps anyone. This distinction matters throughout what follows.
The default mode network
The default mode network (DMN) is a set of interconnected brain regions — including the medial prefrontal cortex and posterior cingulate — that are most active during rest, mind-wandering, and self-referential thought. Excessive or rigid DMN activity has been associated with rumination and is implicated in depression and anxiety. It is worth stating plainly that the DMN is not a harmful or “bad” system: it supports ordinary and necessary functions including autobiographical memory, self-reflection, and future planning. Research interest is not in switching it off but in whether particular patterns — excessive rigidity or altered connectivity — relate to certain psychological states, so “lower DMN activity” should not be read as automatically better.
Brain imaging gives a clear picture of what psychedelics do to this network at full doses. Functional MRI of people given intravenous psilocybin showed reduced activity in, and reduced connectivity within, key DMN hubs. [1] Peer-reviewed Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin doi:10.1073/pnas.1119598109 Broader reviews of the imaging literature describe psilocybin and LSD reducing the coordinated oscillatory activity of these network regions. [2] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 The interpretive hypothesis carried into microdosing is intuitive: if a full dose loosens a rigid, rumination-associated network, perhaps a sub-perceptual dose could nudge the same system gently enough to ease reactivity without producing an experience. That is a reasonable extrapolation — but it is an extrapolation. The robust imaging evidence is at perceptual doses, and microdose-level functional imaging is limited, so the network effect of an actual microdose is not well documented. [3] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
Cellular plasticity: the preclinical core
The strongest mechanistic evidence sits one level down, in the structure of neurons themselves. A landmark study showed that serotonergic psychedelics — including psilocin — promote structural plasticity: they increase the branching complexity of neurons (neuritogenesis), the growth of dendritic spines (spinogenesis), and the formation of functional synapses, both in cultured cells and in living animals. [4] Peer-reviewed Psychedelics Promote Structural and Functional Neural Plasticity doi:10.1016/j.celrep.2018.05.022 The same work tied these changes to signalling through the 5-HT2A receptor and the TrkB and mTOR pathways, and to increases in BDNF, and it grouped psychedelics with ketamine as “psychoplastogens” — compounds that rapidly promote plasticity. [4] Peer-reviewed Psychedelics Promote Structural and Functional Neural Plasticity doi:10.1016/j.celrep.2018.05.022 The term describes a capacity to promote structural plasticity under experimental conditions; it does not imply that every exposure produces meaningful psychological change, and it is not a synonym for therapy. The link back to the receptor mechanism is direct: this is the cascade that 5-HT2A activation sets in motion, as noted in the 5-HT2A mechanism article. [5] Peer-reviewed Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels doi:10.1038/s41386-019-0324-9
And because plasticity is the capacity for change rather than a fixed outcome, what that capacity produces depends on context. A more plastic brain is more able to change, but learning, environment, behaviour, and experience shape what it changes into. This is why the same plasticity-promoting event can have different consequences in different circumstances, and why a mechanism that opens a window for change does not, by itself, determine that the change will be beneficial.
A later study made the case specifically for psilocybin and specifically in vivo. Using two-photon microscopy to image the same neurons over time in mice, researchers found that a single dose of psilocybin produced roughly a ten-percent increase in dendritic spine density in the frontal cortex, appearing within about a day and still present a month later, alongside increased excitatory signalling. [6] Peer-reviewed Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo doi:10.1016/j.neuron.2021.06.008 This is impressive evidence that psilocybin can durably remodel cortical connections — exactly the kind of lasting change the hypothesis requires.
The crucial qualifier is the model. These are findings in cell cultures, flies, and mice, generally at doses well above sub-perceptual. [4] Peer-reviewed Psychedelics Promote Structural and Functional Neural Plasticity doi:10.1016/j.celrep.2018.05.022 [6] Peer-reviewed Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo doi:10.1016/j.neuron.2021.06.008 They establish that the capacity for psychedelic-driven structural plasticity is real and biologically deep. They do not establish that repeated sub-perceptual dosing produces comparable, meaningful remodeling in a human brain.
BDNF: strong in animals, preliminary in humans
Brain-derived neurotrophic factor (BDNF) is a protein central to synaptic growth and plasticity, and it recurs throughout the preclinical findings above as part of the signalling that accompanies psychedelic-induced structural change. [4] Peer-reviewed Psychedelics Promote Structural and Functional Neural Plasticity doi:10.1016/j.celrep.2018.05.022 Because BDNF can be measured in blood, it has been proposed as a convenient human biomarker for whether these plasticity processes are being switched on. That convenience comes with a caveat: blood BDNF is an indirect marker and may not faithfully represent BDNF activity inside specific brain regions, so a change in circulating BDNF is a suggestive signal rather than direct evidence that the brain has been rewired.
The human, low-dose evidence is where caution is essential. One small placebo-controlled study found that single low doses of LSD acutely raised blood plasma BDNF at certain time points relative to placebo. [7] Peer-reviewed Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers doi:10.1021/acsptsci.0c00099 This is suggestive and often cited — but it should be read with the authors’ own framing, which is that confirmation of psychedelic-induced neuroplasticity in humans is largely lacking. [7] Peer-reviewed Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers doi:10.1021/acsptsci.0c00099 It was a single study, with a different drug from psilocybin, measuring a peripheral proxy rather than brain plasticity directly, and subsequent low-dose work has not consistently reproduced a BDNF increase. The accurate summary is that the human microdose-level BDNF signal is preliminary and inconsistent, not established. [3] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
The dose question
Even granting the preclinical plasticity in full, one variable separates it from the microdosing claim: dose. Demonstrating that a compound can trigger plasticity at one level of exposure does not establish the minimum exposure required to do so. The structural studies generally used doses well above sub-perceptual, so the central unanswered question is whether sub-perceptual receptor activation crosses the threshold needed to initiate the same downstream processes at all. [3] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 This connects directly to the receptor occupancy and pharmacokinetic gaps described elsewhere in the cluster: if a microdose engages relatively few receptors and produces low brain exposure, whether it reaches the activation threshold for plasticity is genuinely unknown. [5] Peer-reviewed Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels doi:10.1038/s41386-019-0324-9
The transfer gap
Putting the levels of evidence side by side makes the structure of the problem clear. The cellular plasticity findings are strong but preclinical. The network findings are solid but at full doses. The one human low-dose biomarker finding is preliminary and unreplicated. Each is real within its own scope; the difficulty is that the microdosing claim requires all of them to transfer simultaneously — from animals to humans, from full doses to sub-perceptual ones, and from a molecular marker to a meaningful behavioural outcome. [3] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204 That triple transfer has not been demonstrated, and the controlled studies that test the practice directly have not established benefits beyond expectation. [8] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706 A strong plasticity mechanism explains why the effect is possible; it is not, on its own, evidence that the effect occurs at a microdose.
| Finding | Strength | Where it comes from | Dose level |
|---|---|---|---|
| Structural plasticity (neurites, spines, synapses) | Strong | Cell cultures, flies, mice | Above sub-perceptual |
| Psilocybin-specific spine growth in vivo | Strong | Mice | Above sub-perceptual |
| Default mode network modulation | Solid | Human fMRI | Perceptual (full) doses |
| Acute BDNF increase in humans | Preliminary, inconsistent | One small human study (LSD) | Low/microdose |
| Lasting structural change from human microdosing | Not demonstrated | — | Microdose — untested |
- The right shape of mechanism
- Because the drug clears in hours, a lasting effect must be carried by a durable change; plasticity is the leading candidate precisely because it can outlast the trigger. [6] Peer-reviewed Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo doi:10.1016/j.neuron.2021.06.008
- Psychoplastogens
- In preclinical models, psychedelics including psilocin rapidly promote dendritic and synaptic growth via 5-HT2A, TrkB, mTOR, and BDNF signalling. [4] Peer-reviewed Psychedelics Promote Structural and Functional Neural Plasticity doi:10.1016/j.celrep.2018.05.022
- Default mode network modulation
- Full-dose psilocybin reduces DMN activity and connectivity in human imaging; the microdose-level effect is not well documented. [1] Peer-reviewed Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin doi:10.1073/pnas.1119598109
- BDNF as a human signal
- A single low-dose LSD study found acute BDNF increases, but human confirmation is described as lacking and later low-dose work has not consistently replicated it. [7] Peer-reviewed Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers doi:10.1021/acsptsci.0c00099
- The transfer gap
- The claim needs preclinical, full-dose, and biomarker findings to transfer together to human microdosing — a step that has not been shown. [3] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
Frequently asked questions
What is the neuroplasticity hypothesis for microdosing?
It is the idea that psychedelics produce lasting benefits not by being present in the body — they clear within hours — but by triggering durable changes in how neurons connect. In laboratory and animal studies, psychedelics including psilocin promote the growth of dendrites and synapses and engage signalling linked to the growth factor BDNF. [4] Peer-reviewed Psychedelics Promote Structural and Functional Neural Plasticity doi:10.1016/j.celrep.2018.05.022 The hypothesis is that even sub-perceptual doses might nudge these same plasticity processes. It is a coherent and well-motivated idea; it is not, at microdose levels in humans, a demonstrated fact. [3] Peer-reviewed Microdosing psychedelics: More questions than answers? An overview and suggestions for future research doi:10.1177/0269881119857204
What is the default mode network, and what does psilocybin do to it?
The default mode network is a set of brain regions most active during rest and self-referential thinking, and its overactivity is associated with rumination. Brain imaging shows that full doses of psilocybin reduce the coordinated activity and connectivity of this network. [1] Peer-reviewed Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin doi:10.1073/pnas.1119598109 [2] Peer-reviewed Psychedelics doi:10.1124/pr.115.011478 The hope carried into microdosing is that a much smaller dose could gently modulate the same system. The strong imaging evidence, however, comes from perceptual doses; microdose-level imaging is limited.
Does the BDNF evidence come from people taking microdoses?
Mostly not. The strongest BDNF and plasticity findings come from cell cultures and animals given doses that produce clear effects. [4] Peer-reviewed Psychedelics Promote Structural and Functional Neural Plasticity doi:10.1016/j.celrep.2018.05.022 In humans, one small placebo-controlled study found that low doses of LSD acutely raised blood BDNF at some time points, but the authors themselves noted that confirmation of psychedelic-induced plasticity in humans is largely lacking, and later low-dose studies have not consistently reproduced a BDNF increase. [7] Peer-reviewed Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers doi:10.1021/acsptsci.0c00099 So the human, microdose-level evidence for a BDNF effect is preliminary and mixed.
If the preclinical evidence is strong, why not conclude microdosing works?
Because preclinical strength does not transfer automatically to humans, and full-dose effects do not transfer automatically to microdoses. The plasticity findings are real and impressive in their own setting — cells, animals, and often higher doses. [6] Peer-reviewed Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo doi:10.1016/j.neuron.2021.06.008 Whether repeated sub-perceptual dosing produces comparable, meaningful structural change in a human brain, and whether that change yields the benefits people report, is the step that remains unproven, which is why this cluster keeps mechanism and outcome separate. [8] Systematic review The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706
Does increased neuroplasticity always mean better brain function?
No. Neuroplasticity means the brain can change; it does not specify the direction of the change. Whether a change is helpful depends on which circuits are involved, the conditions under which adaptation occurs, and how the change feeds into behaviour. [4] Peer-reviewed Psychedelics Promote Structural and Functional Neural Plasticity doi:10.1016/j.celrep.2018.05.022 A more plastic brain is more able to change, but that capacity is neutral on its own, so an increase in plasticity or in a marker like BDNF is not the same as an improvement in wellbeing. [7] Peer-reviewed Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers doi:10.1021/acsptsci.0c00099